HTG Molecular Diagnostics, Inc.
HTGMQ
$0.0001
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -12.83% | -15.22% | -50.37% | -28.09% | -17.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.83% | -15.22% | -50.37% | -28.09% | -17.46% |
| Cost of Revenue | -0.48% | -8.41% | -13.73% | 27.05% | 28.66% |
| Gross Profit | -8.72% | -10.64% | -2,482.89% | -668.80% | -120.33% |
| SG&A Expenses | -29.60% | -35.14% | -19.64% | 10.33% | 20.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.73% | -23.94% | -17.06% | 16.44% | 23.63% |
| Operating Income | 19.85% | 27.83% | -2.78% | -39.07% | -36.50% |
| Income Before Tax | 22.23% | 9.65% | -0.58% | -126.39% | -34.07% |
| Income Tax Expenses | 450.00% | 122.22% | -15.79% | -69.94% | -83.33% |
| Earnings from Continuing Operations | 22.20% | 9.61% | -0.57% | -125.17% | -34.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.20% | 9.61% | -0.57% | -125.17% | -34.02% |
| EBIT | 19.85% | 27.83% | -2.78% | -39.07% | -36.50% |
| EBITDA | 18.82% | 27.67% | -4.38% | -41.09% | -38.43% |
| EPS Basic | 76.54% | 45.72% | 32.27% | -36.86% | -1.05% |
| Normalized Basic EPS | 76.55% | 57.10% | 32.27% | 17.50% | -1.09% |
| EPS Diluted | 76.54% | 45.72% | 32.27% | -36.86% | -1.05% |
| Normalized Diluted EPS | 76.55% | 57.10% | 32.27% | 17.50% | -1.09% |
| Average Basic Shares Outstanding | 231.65% | 66.51% | 48.50% | 64.53% | 32.62% |
| Average Diluted Shares Outstanding | 231.65% | 66.51% | 48.50% | 64.53% | 32.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
